Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: Results from the MAINTAIN Nephritis Trial

Annals of the Rheumatic Diseases

Volumn 69, Issue 12, 2010, Pages 2083-2089

  Houssiau, Frédéric A ^a   D'Cruz, David ^b   Sangle, Shirish ^b   Remy, Philippe ^c   Vasconcelos, Carlos ^d   Petrovic, Radmila ^e   Fiehn, Christoph ^f   Garrido, Enrique De Ramon ^g   Gilboe, Inge Magrethe ^h   Tektonidou, Maria ⁱ   Blockmans, Daniel ^j   Ravelingien, Isabelle ^k   Le Guern, Véronique ^l   Depresseux, Geneviève ^a   Guillevin, Loïc ^l   Cervera, Ricard ^g   Abramowicz, Daniel ^m   Atzeni, Fabiola ⁿ   Danieli, Maria Giovanna ^o   De Clercq, Luc ^p   De Keyser, Filip ^q   Delahousse, Michel ^r   Espinosa, Gerard ^g   Golstein, Marc ^s   Hirsch, Marco ^t   Karras, Alexandre ^u   Lang, Philippe ^c   Marchal, Martine ^v   Marinho, Antonio ^d   Max, Regina ^v   Peeters, Patrick ^q   Petera, Peter ^w   Quémeneur, Thomas ^x   Raeman, Frank ^y   Sarzi Puttini, Piercarlo ⁿ   De Santis, Lucia Valiente ^g   Verresen, Luc ^z   Weiss, Laurence ^j   Westhovens, René ^a   more..

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c HENRI MONDOR HOSPITAL   (France)

^d HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^e UNIVERSITY OF BELGRADE   (Serbia)

^f Center for Rheumatic Diseases   (Germany)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF ATHENS   (Greece)

^j UNIVERSITY OF LEUVEN   (Belgium)

^k OLV HOSPITAL   (Belgium)

^l Hôpital Cochin ^*  (France)

^m ERASME HOSPITAL   (Belgium)

ⁿ UNIVERSITY OF MILAN   (Italy)

^o UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^p SINT AUGUSTINUS HOSPITAL   (Belgium)

^q GHENT UNIVERSITY HOSPITAL   (Belgium)

^r FOCH HOSPITAL   (France)

^s St Jean Hosp   (Belgium)

^t Hôpital Européen Georges Pompidou ^*

^u Cardiology   (Belgium)

^v UNIVERSITY OF HEIDELBERG   (Germany)

^w LILLE UNIVERSITY HOSPITAL   (France)

^x Jan Palfijn Hospital   (Belgium)

^y DEPARTMENT OF CARDIOLOGY   (Belgium)

^z HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C3; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HEMOGLOBIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ADULT; ALBUMIN BLOOD LEVEL; ALOPECIA; AMENORRHEA; ANEMIA; ANGINA PECTORIS; ARTICLE; AVASCULAR NECROSIS; BACTERIAL INFECTION; CEREBROVASCULAR ACCIDENT; CHICKENPOX; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CUSHING DISEASE; CYTOMEGALOVIRUS INFECTION; CYTOPENIA; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG PULSE THERAPY; FEMALE; FOLLOW UP; GENITAL BLEEDING; HEPATITIS; HERPES SIMPLEX; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY HEMATOMA; KIDNEY VEIN THROMBOSIS; LEGIONNAIRE DISEASE; LEUKOPENIA; LONG TERM CARE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUSCLE BLEEDING; NAUSEA; NEPHROTIC SYNDROME; OSTEOPENIA; PRIORITY JOURNAL; PROTEINURIA; PSOAS BLEEDING; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETINOPATHY; RIB FRACTURE; SALMONELLOSIS; SCORING SYSTEM; SEPSIS; SIDE EFFECT; STREPTOCOCCUS PNEUMONIA; SUBCLAVIAN VEIN THROMBOSIS; URINARY TRACT INFECTION; UTERINE CERVIX CARCINOMA; VEIN THROMBOSIS;

ADULT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649751475     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.131995     Document Type: Article

References (24)

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999;10:413-24.
2. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003;82:299-308.
3. Austin HA, 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-19.
4. Boumpas DT, Austin HA, 3rd, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
5. Gourley MF, Austin HA, 3rd, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 1996;125:549-57.
6. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62.
7. Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
8. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12.
9. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
10. Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-40.
11. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010;69:61-4.
12. El Hachmi M, Jadoul M, Lefèbvre C, et al. Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus 2003;12:692-6.
13. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
14. Vitali C, Bencivelli W, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992;10:541-7.
15. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
16. Le Meur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007;7:2496-503.
17. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
18. Wofsy D, Appel GB, Dooley MA, et al. Aspreva Lupus Management Study maintenance results. Lupus 2010;19(Suppl):27 (CS12.5).
19. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-406.
20. Morath C, Schwenger V, Beimler J, et al. Antifibrotic actions of mycophenolic acid. Clin Transplant 2006;20 (Suppl 17):25-9.
21. Kaczmarek I, Ertl B, Schmauss D, et al. Preventing cardiac allograft vasculopathy: long-term beneficial effects of mycophenolate mofetil. J Heart Lung Transplant 2006;25:550-6.
22. Davies R, Sangle SR, Murru V, et al. A randomized controlled trial of mycophenolate mofetil versus placebo on surrogate markers of atherosclerosis in systemic lupus erythematosus. ACR/ARHP Annual Scientific Meeting. Arthritis Rheum 2009;(Suppl):103A.
23. Nguyen T, Vacek PM, O'Neill P, et al. Mutagenicity and potential carcinogenicity of thiopurine treatment in patients with inflammatory bowel disease. Cancer Res 2009;69:7004-12.
24. Anderka MT, Lin AE, Abuelo DN, et al. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A 2009;149A: 1241-8.